Generic-drug maker Mankind Pharma remains bound to its commitment not to challenge the validity of a patent covering Allergan’s glaucoma medication, Lumigan. This comes after a federal judge in Delaware dismissed Mankind’s argument that recent rulings concerning obviousness-type double patenting have shifted the litigation landscape. The court’s decision underscores the enforceability of settlement agreements in pharmaceutical patent litigation, potentially setting a precedent for future cases involving similar disputes. For further details, see the original article here.